133 related articles for article (PubMed ID: 37606840)
21. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients.
Corsi F; Albasini S; Sorrentino L; Armatura G; Carolla C; Chiappa C; Combi F; Curcio A; Della Valle A; Ferrari G; Gasparri ML; Gentilini O; Ghilli M; Listorti C; Mancini S; Marinello P; Meani F; Mele S; Pertusati A; Roncella M; Rovera F; Sgarella A; Tazzioli G; Tognali D; Folli S
Breast; 2021 Dec; 60():131-137. PubMed ID: 34624755
[TBL] [Abstract][Full Text] [Related]
23. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
[TBL] [Abstract][Full Text] [Related]
24. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
Poterala JE; Havighurst T; Braun Wisinski K
Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
[TBL] [Abstract][Full Text] [Related]
26. Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics.
Kim WH; Kim HJ; Park HY; Park JY; Chae YS; Lee SM; Cho SH; Shin KM; Lee SY
Ultrasound Med Biol; 2019 Mar; 45(3):702-709. PubMed ID: 30567630
[TBL] [Abstract][Full Text] [Related]
27. Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
Maimaitiaili A; Chen H; Xie P; Liu Z; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; He J; Fan Z; Zhang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8769-8778. PubMed ID: 37129606
[TBL] [Abstract][Full Text] [Related]
28. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
Boughey JC; Hoskin TL; Goetz MP
Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
[TBL] [Abstract][Full Text] [Related]
30. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
31. Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.
Al-Hattali S; Vinnicombe SJ; Gowdh NM; Evans A; Armstrong S; Adamson D; Purdie CA; Macaskill EJ
Cancer Imaging; 2019 Dec; 19(1):91. PubMed ID: 31878958
[TBL] [Abstract][Full Text] [Related]
32. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.
Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M
Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489
[TBL] [Abstract][Full Text] [Related]
34. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
35. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
[TBL] [Abstract][Full Text] [Related]
36. Predicting Post Neoadjuvant Axillary Response Using a Novel Convolutional Neural Network Algorithm.
Ha R; Chang P; Karcich J; Mutasa S; Van Sant EP; Connolly E; Chin C; Taback B; Liu MZ; Jambawalikar S
Ann Surg Oncol; 2018 Oct; 25(10):3037-3043. PubMed ID: 29978368
[TBL] [Abstract][Full Text] [Related]
37. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
Fayanju OM; Ren Y; Greenup RA; Plichta JK; Rosenberger LH; Force J; Suneja G; Devi GR; King TA; Nakhlis F; Hyslop T; Hwang ES
Breast Cancer Res Treat; 2020 Feb; 180(1):207-217. PubMed ID: 31960171
[TBL] [Abstract][Full Text] [Related]
38. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
[TBL] [Abstract][Full Text] [Related]
39. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?
Cerbelli B; Botticelli A; Pisano A; Campagna D; De Vincentiis L; Pernazza A; Frusone F; Scavina P; Monti M; Fortunato L; Costarelli L; d'Amati G
Breast J; 2019 Mar; 25(2):273-277. PubMed ID: 30734420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]